In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Massachusetts General Hospital

http://www.massgeneral.org

Latest From Massachusetts General Hospital

Obesity Market Potential Is Huge, But Access To Drugs An Increasing Challenge

Despite double-digit weight loss across several drugs presented at ADA, experts note access to obesity therapies will be constrained without outcomes data to justify their widespread use and cost.

Market Access Clinical Trials

Asia Deal Watch: HanAll, Daewoong Team With US Biotech In Parkinson's

Sino acquires Gmax's obesity drug candidate. Simcere partners with Mass General Brigham on select research projects.

Deal Watch Business Strategies

Finance Watch: Another VC Mega-Round As Flare Raises $123m Series B

Private Company Edition: Flare Therapeutics, targeting transcription factors to discover precision medicines, had big pharma backing for its second venture capital financing. Also, Mediar closed a $10m series A round, Switch launched with $52m and EpiBiologics raised a $50m series A round.

Financing Innovation

Prilenia Plans To Continue With Pridopidine In ALS Despite Platform Study Miss

Pridopidine is the latest ALS drug candidate to miss the primary endpoint in the HEALEY-ALS platform study, but the S1R agonist did indicate potential benefits in speech and a key biomarker of the disease.

Clinical Trials Drug Approval Standards
See All

Company Information

  • Industry
  • Academic and Research Institutions
UsernamePublicRestriction

Register